Tengion needs to be saved. The father of this whole blasted technology, Atala, is a urologist who is trying to make people's lives more comfortable. These people lose their bladders and have little hope of normalcy. The chief technology officer for ONVO is a former Tengion researchers. They would be synergistic and connect east and west coast.
Tengion is bleeding, but it deserves to finish its breakthrough study.
ONVO should be contacting philanthropists, or gulp, dilute more shares to buy it.
forgive my ignorance but how does Tengion tie into Organovo? Is there a partnership or some other business nexus not commonly known? Do articles exist linking the two companies through research arrangements or sourcing agreements? Just wondering as Tengion seemed to spawn more discussion on the ONVO board today than ONVO did. Honest questions - no sarcasm here, just seeking info. Thanks in advance.
Here is the rub. Tengion will eventually sacrifice its study to stay afloat, and backers will bleed dry. For instance, Ampe is a company that makes its living picking up dropped drug studies and starting them all over again. Tengion can't just drop its study. Maybe you can envision tengion's studies being save after filing for dissolution, but I think it compromises the ongoing trials.